PharmaCyte Biotech, Inc.PMCBNASDAQ
Loading
Asset Growth Recovery in ProgressRecovering
Percentile Rank95
5Y CAGR+3.5%
Year-over-Year Change
Year-over-year total asset growth rate
5Y CAGR
+3.5%/yr
Long-term compound
Percentile
P95
Near historical high
vs 5Y Ago
1.2x
Modest growth
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 24.09% |
| Q3 2025 | -18.23% |
| Q2 2025 | 25.87% |
| Q1 2025 | -20.45% |
| Q4 2024 | -21.51% |
| Q3 2024 | 17.18% |
| Q2 2024 | -16.05% |
| Q1 2024 | -9.53% |
| Q4 2023 | -1.26% |
| Q3 2023 | 9.01% |
| Q2 2023 | -6.00% |
| Q1 2023 | -5.34% |
| Q4 2022 | -5.76% |
| Q3 2022 | -3.57% |
| Q2 2022 | -1.43% |
| Q1 2022 | -0.40% |
| Q4 2021 | 1290.76% |
| Q3 2021 | -10.36% |
| Q2 2021 | -10.38% |
| Q1 2021 | -7.60% |
| Q4 2020 | 20.31% |
| Q3 2020 | 20.52% |
| Q2 2020 | 15.52% |
| Q1 2020 | -0.00% |
| Q4 2019 | -4.78% |
| Q3 2019 | -3.05% |
| Q2 2019 | -0.93% |
| Q1 2019 | -3.79% |
| Q4 2018 | -14.33% |
| Q3 2018 | 10.42% |
| Q2 2018 | -4.64% |
| Q1 2018 | -15.04% |
| Q4 2017 | -16.90% |
| Q3 2017 | 9.89% |
| Q2 2017 | 13.82% |
| Q1 2017 | 13.12% |
| Q4 2016 | -10.53% |
| Q3 2016 | 5.07% |
| Q2 2016 | -10.52% |
| Q1 2016 | 4.71% |